ライフサイエンスコーパス: amikacin

1 ient who was in renal failure (8.7 microg/mL amikacin).

2 cs, which usually include co-trimoxazole and amikacin.

3 d by fourfold by day 7 after the addition of amikacin.

4 eta-lactams and close to those observed with amikacin.

5 g combination clarithromycin, cefoxitin, and amikacin.

6 with four that were known to be treated with amikacin.

7 ed killing and the aminoglycoside antibiotic amikacin.

8 namycin and those resistant to kanamycin and amikacin.

9 ing of one of the aminoglycoside substrates, amikacin.

10 to cefoxitin, clarithromycin, imipenem, and amikacin.

11 pretive category was lowest for imipenem and amikacin.

12 o 0.5 mug/ml), ofloxacin (0.25 to 2 mug/ml), amikacin (0.25 to 2 mug/ml), kanamycin (0.25 to 2 mug/ml

13 l injection of ceftazidime (2 mg/0.1 ml) and amikacin (0.4 mg/0.1 ml) was performed without retinecto

14 Intravitreal injections of amikacin (0.4 mg/0.1 mL) were given in 14 of 19 patients

15 or Streptomyces isolates that suggested that amikacin (100% susceptibility for 92 isolates tested) an

16 ities to tested isolates were the following: amikacin (14/16; 87.5%) and clarithromycin (12/16, 75.0%

17 utol, versus 42% for clarithromycin, 19% for amikacin, 18% for rifampicin, and 11% for moxifloxacin.

18 broth macrodilution method were as follows: amikacin, 2 microg/ml; Bay y 3118, 0.015 microg/ml; clar

19 10(6) bacteria for 1 h and then treated with amikacin (200 microg/ml) for 2 h to selectively kill ext

20 versus 1 microg/ml), and the aminoglycosides amikacin (32 microg/ml versus 16 microg/ml), gentamicin

21 (P < 0.0001) more likely to be resistant to amikacin (37%, 31/84) than were methicillin-susceptible

22 atments every 8 hrs of gentamicin (80 mg) or amikacin (400 mg) for 14 to 21 days.

23 %); gram-negative bacteria were sensitive to amikacin (5/5, 100%).

24 istance rates of CRKP isolates were high for amikacin (59.2%) and fluoroquinolones (>97%).

25 drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionami

26 n, levofloxacin, or moxifloxacin), 99.2% for amikacin, 99.2% for capreomycin, and 96.4% for kanamycin

27 ne-third of the isolates were susceptible to amikacin (a very major error).

28 one or in combination with ethionamide (Et), amikacin (A), and Z given for 2 or 7 months.

29 We recommend primary testing of amikacin against isolates of the MAC and propose MIC gui

30 Birds were treated with either Amikacin alone to kill high-frequency hair cells or Amik

31 Resistance to amikacin (AMK) and kanamycin (KAN) in clinical Mycobacte

32 ed from endophthalmitis to vancomycin (VAN), amikacin (AMK), and ceftazidime (CEF).

33 ance to INH, the fluoroquinolone (FQ) drugs, amikacin (AMK), and kanamycin (KAN).

34 (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) u

35 lates to the following antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanate, ceftriaxo

36 Amikacin, an aminoglycoside antimicrobial agent, was add

37 us, isolates with constitutive resistance to amikacin and clarithromycin were isolated from several i

38 majority of the isolates were susceptible to amikacin and clarithromycin.

39 s observed between HELZJ and the antibiotics amikacin and gentamicin, which resulted in decreased bac

40 es collected from 413 dogs were analyzed for amikacin and methicillin resistance using broth microdil

41 mino groups of the aminoglycoside antibiotic amikacin and of its acetylated derivatives.

42 ntous cells with cefoxitin and ceftriaxone), amikacin and phages did not modify cell shape but produc

43 timicrobials, the infection was treated with amikacin and polymyxin B-trimethoprim, and the ulcer res

44 n alone to kill high-frequency hair cells or Amikacin and sound exposure to target hair cells across

45 with an intravitreal injection of vancomycin-amikacin and vancomycin-ceftazidime, respectively, which

46 hthalmitis bacterial isolates to vancomycin, amikacin, and ceftazidime over a 23-year period.

47 0% for all others), followed by doxycycline, amikacin, and ciprofloxacin.

48 aterial to antibiotics cefepime, ampicillin, amikacin, and erythromycin was proposed.

49 of susceptibility to gentamicin, tobramycin, amikacin, and erythromycin were obtained for N. nova, N.

50 The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capre

51 amic indices for rifampicin, clarithromycin, amikacin, and moxifloxacin are seldom met.

52 cluding gentamicin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on angiogenin-

53 eptible to ampicillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had redu

54 The aminoglycosides kanamycin and amikacin are important bactericidal drugs used to treat

55 t to kanamycin may not be cross-resistant to amikacin, as is often assumed.

56 sides, including gentamicin, tobramycin, and amikacin, but they varied in their susceptibility to flu

57 The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide.

58 Mycobacterium chelonae) were tested against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxy

59 erium chelonae isolates) were tested against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxy

60 solates to be susceptible or intermediate to amikacin, cefoxitin, imipenem, and the fluoroquinolones

61 otic activity was tested for clarithromycin, amikacin, cefoxitin, tigecycline, and bedaquiline (TMC20

62 +/-1 dilution of the MIC mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxaci

63 Categorical results for amikacin, ciprofloxacin, gatifloxacin, gentamicin, imipe

64 All isolates were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethopri

65 These results suggest that a combination of amikacin, clarithromycin, and rifabutin may be the most

66 high levels of resistance; susceptibility to amikacin, clarithromycin, tobramycin (only in M. chelona

67 ng activities of six 2-agent combinations of amikacin, doripenem, levofloxacin, and rifampin were qua

68 ambutol, and pyrazinamide, supplemented with amikacin during the first 2 months.

69 n of ETA, in combination with the antibiotic amikacin, enhanced the survival of mice infected with a

70 Invasion was quantified by amikacin exclusion assays.

71 tigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pu

72 etobacter baumannii-calcoaceticus complex to amikacin, gentamicin, and tobramycin using disk diffusio

73 etion of the acrD gene decreased the MICs of amikacin, gentamicin, neomycin, kanamycin, and tobramyci

74 The N3 amino groups of butirosin A and amikacin have lowered pKa values, which is attributed to

75 3 (94%) eyes and intravitreal vancomycin and amikacin in 4 of 63 (6%) eyes.

76 tra- and inter-ring NOEs for butirosin A and amikacin in their respective ternary complexes with APH(

77 luded cephalosporin, in 576 (70%) cases, and amikacin, in 233 (28%).

78 significantly associated with resistance to amikacin irrespective of methicillin resistance.

79 Amikacin is a first-line treatment for Aeromonas infecti

80 Amikacin is a major drug used for the treatment of Mycob

81 oniazid, rifampin, streptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxaci

82 oniazid, rifampin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxaci

83 lity for phleomycin, bleomycin, capreomycin, amikacin, kanamycin, cetylpyridinium chloride, and sever

84 amycin, a fluoroquinolone, and at least 1 of amikacin, kanamycin, or capreomycin based on drug suscep

85 Ten isolates (2.1%) had an initial amikacin MIC of >64 mug/ml, of which seven (1.5%) had MI

86 entration (MIC) <or=40 microg/mL] but not to amikacin (MIC <4 microg/mL).

87 ocycline = doycycline (MIC90, 4 microg/ml) > amikacin (MIC90, 8 microg/ml).

88 This study presents in vitro amikacin MICs for 462 consecutive clinical isolates of t

89 Approximately 50% of isolates had amikacin MICs of 8 mug/ml, and 86% had MICs of </=16 mug

90 array containing gene aacA4, which codes for amikacin, netilmicin, and tobramycin resistance; a chlor

91 either systemic antibiotics (ceftazidime and amikacin) or no systemic antibiotics.

92 cy records indicated the preferential use of amikacin over other aminoglycosides in the burn intensiv

93 Amikacin plus doripenem was the most effective combinati

94 ng effect in time-kill studies was seen with amikacin plus doripenem.

95 In contrast, amikacin plus levofloxacin was found to be antagonistic

96 y loads in spleen whereas clarithromycin and amikacin prevented death but had little impact on bacill

97 Amikacin prophylaxis is a useful strategy for preventing

98 isolates that share the property of in vitro amikacin resistance are grouped together by some authors

99 he 422 isolates, 32 that tested positive for amikacin resistance by broth microdilution or disk diffu

100 Amikacin resistance, rare among nocardiae, was observed

101 Our examination of 13 isolates that are amikacin resistant has revealed the existence of three d

102 SMA patient fibroblasts with tobramycin and amikacin resulted in a quantitative increase in SMN-posi

103 to wild-type levels, increased resistance to amikacin returned to wild-type sensitivity, and high lev

104 lycosides (kanamycin, gentamycin, sisomycin, amikacin, spectinomycin, neomycin), macrolides-lincosami

105 The TRNOE spectra for amikacin suggest that the 6-amino-6-deoxy-D-glucose ring

106 ubstituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl substituent, althoug

107 howed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and

108 Amikacin, tigecycline, and the carbapenems were active i

109 ted with M.bovis BCG[pMind-Lx], treated with amikacin to kill extracellular bacteria, and then incuba

110 strain of Aeromonas hydrophila resistant to amikacin, tobramycin, and multiple cephalosporins.

111 s induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight prematur

112 Invasion assays with amikacin treatment demonstrated that nocardiae were inte

113 ith a reduction in the incidence of SSIs was amikacin use as antibiotic prophylaxis.

114 ncentration established for levofloxacin and amikacin was 1.5 microg/ml, that established for capreom

115 ed by our quantitative method, cefepime plus amikacin was found to be the most superior combination,

116 antimicrobial agents except clindamycin and amikacin was significantly reduced.

117 Amikacin was the most active agent against Pseudomonas a

118 The aminoglycoside antibiotic amikacin was used to study the intracellular growth of M

119 methods for a few drugs (e.g., cefoxitin and amikacin) was poor.

120 ested antimicrobials, except carbapenems and amikacin, was observed in a proportion of hvKP strains,

121 alues of the amino groups of butirosin A and amikacin were determined by 15N NMR spectroscopy.

122 slow effect, both tested phages, as well as amikacin, were able to rapidly abolish the bacterial gro